Egalet a/s is a specialty pharma company within pain management. Egalet a/s develops a portfolio of opioid formulations for pain management based on a novel, proprietary erosion technology ADPREM (abuse deterrent prolonged release erosion matrix). The range of products is characterized by drug abuse deterrence, a unique plasma profile and avoidance of dose dumping in alcohol.

Abuse of prescription opioid formulations has accelerated in the last ten years in particular in the US and has now passed the illicit use of marijuana. One of four US high school seniors abuse these formulations on a daily basis and more than 13% of the US population above the age of 12 years have experience of misuse of these compounds. There is a great need to market drug abuse resistant opioid formulations to counteract this development.

An ideal plasma profile for chronic opioid management should ensure rapid onset for immediate pain relief, a low Cmax to reduce side effects and a plasma concentration ensuring pain relief for 24 hours.

Dose dumping in alcohol is a common phenomenon with opioids ultimately forcing the withdrawal of PALLADONETM from the US market in 2005. Most opioid formulations in the US accordingly carry a black box warning to prevent this problem. There is a need to market opioid formulations that are not subject to interaction with alcohol to ensure patient safety and life quality.

Egalet a/s has developed three distinct, proprietary, oral administration technologies addressing particular challenges like drug abuse mentioned above, but also chronotherapy as well as oral dosing of large amounts of API to infants and geriatric patients. Egalet a/s pursues the development of products in the two latter technologies with pharmaceutical partners.